InvestmentUpdated on 23 June 2026
Pre-Series A equity fundraise
Clinical Director at CanSense Ltd
About
CanSense has raised £1.5M (JPY32M) in seed investment and £2.4M (JPY514M) in non-dilutive funding to bring its colorectal cancer diagnostic blood test to market in the UK. With regulatory milestones achieved and international patents awarded CanSense seek investment to expand into other global territories and expand it's indications to other cancer types.
Stage
- Series A | Scale business
Organisation
Similar opportunities
Project cooperation
Clinical trial sites for clinical performance Study in colorectal cancer
- Technical
- Capital contribution
- Strategic Partnership
- Completing the consortia
- Consortium seeks Partners
- Technological contribution
- Design - setting the project scope
Dean Harris
Clinical Director at CanSense Ltd
Service
Colorectal cancer diagnostic testing
- Testing & Analysis
- Research & Development
Dean Harris
Clinical Director at CanSense Ltd
Service
- Testing & Analysis
- Research & Development
Dean Harris
Clinical Director at CanSense Ltd